iLoF

Many diseases without treatments are heterogeneous and complex, requiring stratification based on biological profiles for suitable treatments. Personalized drug development is challenging, with many clinical studies canceled due to unpromising results or budget issues, especially in neurodegenerative diseases like AD. For which, >400 AD studies failed due to poor biological knowledge, disease heterogeneity, and trial challenges.
The top 4 pharma companies spend >€400M/year on AD screening with 90% of patients leave trials due to invasive and expensive testing (€4k/patient). From the remaining, 80% are discarded making AD drug discovery 2X as expensive as average. Due to these issues, many potentially effective drugs are abandoned.

iLoF is a unique platform with an innovative approach for various use cases. Our key selling points include cost-saving pricing, reproducibility, accuracy, rapid results (<30 seconds), and minimal invasiveness. Our label-free, agnostic test uses a blood sample without consuming it, allowing for continued analysis or freezing for reuse, working on current biomarkers and future targets.

In our beachhead market, we cut costs and time for Alzheimer’s trial recruitment. Traditional methods (PET, MRI, ELISA) consume samples. Our label-free technique does not.

We monitor competitors in blood-based screening but find their solutions less scalable, lower in performance, and more costly due to complex procedures and expensive reagents.

Pre-screening model:
We offer a risk-free, service-based model with a dynamic pricing. Our pricing is directly tied to the savingsfor our customer, it includes a fixed fee plus a variable fee per “positive” result, with most revenue generated when client value exists (if no money is saved, the test is mostly free).

Pricing adapts to each trial, based on base cost per extensive screening (e.g., PET) and current inclusion rate (% of people discarded after screening, e.g., 80% in AD)
Stratifying 1500 patients saves €6M for a trial, with €2M for us.

Drug Discovery Model:
Biomarker validation, trial tracking: Platform fee (per month, per user)
New targets discovery: Platform fee (per month, per user) + Royalty/Shared IP on new targets (milestone-based, per R&D evolution)

Addressable market size in USD: 2 bil (Source)

---

In 2019, we conducted a study with over 100 stakeholders from 15+ countries to identify drug discovery pain points and determine iLoF’s value.
As a result, we engaged with 15+ stakeholders across four continents, including hospitals, biotechs, and two global pharmaceutical companies.
We are generating early revenue through engagements with biotechs and research institutes, validating our platform with ongoing paid pilots. Current pilots include two AD projects: one in Portugal with >10 hospitals, and another with an international AD study across the USA, CA & the UK. Additionally, we have a pilot with the Karolinska Institutet.
With our technology validated, we plan to hire sales executives to secure larger projects with CROs, pharmaceutical companies, and biotechs.

The next milestones we plan to achieve for our go-to-market in Q4 2024 are:

- Finalize technical development: increase the size of our cloud library and improve our platform's accuracy and reliability - ongoing
- Large clinical validation study - ongoing
- Commercial validation study to demonstrate cost & time savings
- Obtain ISO13485

We aim to scale market penetration, reaching about €2M revenue by securing 3 larger deals via CROs or directly with global pharmaceutical partners by 2025. In 2026, we plan to intensify channel building to reach the US and Canada. We project revenue growth to €26M in 2027 by expanding our customer base.